July 26: The Week in Cancer News
Double mastectomy doesn’t lead to a survival advantage over lumpectomy or single mastectomy, and research explores hearing loss linked to cisplatin.
Double mastectomy doesn’t lead to a survival advantage over lumpectomy or single mastectomy, and research explores hearing loss linked to cisplatin.
Standard screening may not catch endometrial cancer in Black women, and a cancer patient receives a voice box transplant for the first time.
Neuropathy may be prevented with an exercise program, and prostate cancer screening standards may not be appropriate for transgender women taking estrogen.
Immune checkpoint inhibitors are effective against non-small cell lung cancer in some patients. Researchers are investigating who benefits from the drugs and when they should be administered for maximum impact.
With the FDA’s approval of the first tumor‑infiltrating lymphocyte (TIL) therapy to treat advanced melanoma, researchers seek to expand this type of cellular therapy to other solid tumors.
The drug showed promise in treating small cell lung cancer that had progressed during or after chemotherapy.
Acupuncture helps manage side effects of endocrine therapy, and adding chemotherapy before surgery delays progression in pancreatic cancer.
Patients given waivers to participate in A trial had outcomes the same or slightly better than people who met the standard requirements; findings support broader and more inclusive trial designs. Cancer patients sometimes find...
The FDA issued its first approval for the use of A KRAS G12C inhibitor in a tumor type other than lung. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to adagrasib...
Risk for cancer and cardiovascular disease linked to air pollution, and three cancer drugs could face generic competition by 2028.